Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Eli Lilly And Co (LLY) Price & Performance

iShares MSCI United Kingdom (FTSE)Trade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

iShares MSCI United Kingdom (FTSE) vs Eli Lilly And Co — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $48.31, while Eli Lilly And Co trades at $1,216.3 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while iShares MSCI United Kingdom (FTSE) pays none. Which is the better fit depends on your goals.

EWULLY
Sector
Broad Market / FactorHealth
52-Week High
$48.68$1.24K
52-Week Low
$40.90$639.43
Market Cap
$1.08T
Enterprise Value
$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI United Kingdom (FTSE)

EWU, the iShares MSCI United Kingdom ETF, trades at $48.38, down 0.23% on the day, with a bullish technical signal driven by moving averages. The ETF tracks UK large-cap equities, facing mixed sentiment from oil price volatility and geopolitical tensions in the Middle East. Recent institutional activity includes Balefire LLC acquiring shares and Bank of America reducing its stake, reflecting divergent views on UK market exposure.

The outlook for EWU hinges on UK economic resilience amid political transitions and energy market fluctuations. Opportunities include diversification into developed market leaders, but risks involve sustained oil price pressures and regional instability. Analyst consensus remains neutral, with the ETF serving as a tactical play on British equities rather than a growth-centric investment.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI United Kingdom (FTSE)

EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.

Read more on EWU

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY